Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages

PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.

Subsidie
€ 1.500.000
2025

Projectdetails

Introduction

Amid the antibiotic resistance crisis, the century-old practice of phage therapy, the use of bacterial viruses to treat bacterial infections, has gained renewed attention. Despite extensive research and clear-cut advantages over antibiotics, phage therapy has yet to gain momentum. This is primarily due to remaining limitations, e.g., the time-consuming process of identifying suitable phages and limited in vivo efficacy.

Proposed Solution

With PHAGE-PRO, I propose a new technology to overcome the shortcomings of traditional phage therapy. Unlike the conventional use of lytic phages, I will capitalize on prophages – viruses that integrate into bacterial genomes capable of excision and replication.

Benefits of PHAGE-PRO

By integrating prophages into safe carrier strains, originating from probiotics, I will unlock two pivotal benefits:

  1. Rapid identification of suitable phages using advanced machine learning.
  2. Sustained in-vivo efficacy.

Yet, the core advantage of PHAGE-PRO lies in its unparalleled synergy of phage killing and pathogen competitive exclusion imposed by the probiotic.

Development Process

To realize this concept, the development of predictive tools is essential to quickly identify the most promising prophages and probiotic combinations for each pathogen (WP1).

Prophage Engineering

Prophage engineering (WP2), followed by rigorous in vitro testing, will ensure high safety and efficacy. High-throughput in vivo experiments using wax moth larvae will reveal the most promising candidate, which I will subsequently validate through a proof of principle experiment using a poultry model (WP3).

Broader Impact

Although I initially tailored PHAGE-PRO to treat Salmonella infections in poultry, its impact extends far beyond. This new technology holds the potential for transformative changes in phage therapy, not only advancing infection management in livestock farming through the enhancement of animal health and the assurance of food product safety, but also by opening the door for targeted preventive and therapeutic interventions in human medicine.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.500.000
Totale projectbegroting€ 1.500.000

Tijdlijn

Startdatum1-1-2025
Einddatum31-12-2029
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENpenvoerder
  • HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC COG

In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR

This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.

€ 1.999.780
ERC COG

Phage infection of bacterial biofilm

This project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections.

€ 1.992.976
ERC ADG

Breaking resistance of pathogenic bacteria by chemical dysregulation

The project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy.

€ 2.499.785
ERC POC

Tuneable Conditional Control of Engineered Bacterial Therapeutics

This project aims to develop a modular synthetic receptor platform for precise control of engineered bacteria in cancer therapy, enhancing safety and efficacy through conditional therapeutic release.

€ 150.000